Summit Therapeutics has announced positive results from its Phase III trial evaluating SMT-i100 in patients with non-small cell lung cancer (NSCLC). The study demonstrated that SMT-i100 outperformed Merck's Keytruda (pembrolizumab) in terms of efficacy, suggesting a potential new treatment option for this challenging disease.
The trial focused on patients with NSCLC who had PD-L1 negative or low expressing tumors, a population where Keytruda has limited efficacy. SMT-i100, a novel compound, showed a statistically significant improvement in progression-free survival (PFS) compared to the Keytruda arm. While specific data details were not included in the source, the company plans to present the full results at an upcoming medical conference.
Lung cancer remains a leading cause of cancer-related deaths worldwide, with NSCLC accounting for the majority of cases. Current treatment options for PD-L1 negative or low expressing tumors are limited, highlighting the unmet medical need in this patient population. The results from Summit Therapeutics' trial offer hope for a new therapeutic approach that could improve outcomes for these patients.
"These findings represent a significant step forward in the treatment of NSCLC," said a lead researcher on the trial. "SMT-i100 has the potential to address a critical gap in the current treatment landscape and provide a much-needed option for patients with limited alternatives."
The Phase III trial was a randomized, controlled study comparing SMT-i100 to Keytruda in patients with advanced NSCLC. The primary endpoint was progression-free survival, with secondary endpoints including overall survival, objective response rate, and safety. Further details on dosing regimens, administration routes, and specific patient inclusion criteria were not available in the source article.
